Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
February 22, 2021 08:00 ET | Source: Aevitas Therapeutics, Inc. Aevitas Therapeutics, Inc.
Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer. Dr. Peters was most recently the Chief Operating Officer of Gemini Therapeutics after serving as the Chief Commercial Officer of Agilis Biotherapeutics. Dr. Peters will lead the Company as it advances its proprietary platform designed to deliver engineered, fully functional, shortened comple